Building upon previous efforts, Parkinson’s UK has opened a monthlong marketing campaign aiming for a better understanding of Parkinson’s disease — particularly among young adults — and of the daily challenges facing patients, caregivers, and family members. Specifically, the group wants to help people more deeply understand and care…
Researchers developed “mini-brains” — midbrain-like organoids — that recapitulate for a first time two key Parkinson’s hallmarks in that organ: the formation of toxic protein clumps known as Lewy bodies and the loss of dopamine-producing neurons. A combination of two known Parkinson’s risk factors — a deficiency of the beta-glucocerebrosidase…
A walking program seems to boost the benefits of respiratory muscle training — which consists of specific exercises designed to improve the function of muscles used in breathing — in people with Parkinson’s disease, a small study has found. In the study, patients who followed an eight-week walking program…
One in three people with early to mid-stage Parkinson’s disease were found to have difficulties in learning a new task by following instructions. The deficits were more prone during the early stages of learning, when new memories are being made, and were linked to poorer activation of certain brain…
The Silverstein Foundation for Parkinson’s with GBA is supporting early work by AcureX Therapeutics to bring into patient testing potential disease-modifying treatments for Parkinson’s disease. Specifically, grant funding will go to advance the development of small molecule compounds targeting the path involving a specific protein in mitochondria — the…
Bial has entered into an exclusive agreement to market upon approval in Europe APL-130277 — Sunovion Pharmaceuticals‘ sublingual (under the tongue) film of apomorphine for off episodes in Parkinson’s disease. Under the agreement’s terms, Bial will be responsible for preparing a marketing authorization application for regulatory agencies there — drawing on…
The American Parkinson Disease Association (APDA) has awarded $1.85 million to research projects focused on innovative tools and strategies to advance care and treatment of Parkinson’s disease for the 2021–2022 funding year. For the second year in a row, ADPA’s annual research funding included specialized grants to projects focused…
A previous diagnosis of bipolar disorder negatively affects the course of Parkinson’s disease, and is associated with greater neuropsychiatric and cognitive problems, poorer treatment outcomes, and shorter survival, a study shows. Also, a greater proportion of Parkinson’s patients with preexisting bipolar disorder had a history of either condition in…
The Adira Foundation is inviting people with neurodegenerative diseases and their caregivers to join a grant proposal review committee. A nonprofit foundation, its mission is to unite people affected by some of most common neurodegenerative diseases — namely, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, amyotrophic lateral sclerosis, and…
Daily consumption of sweet marjoram tea, in addition to standard antiparkinsonian medication, may help reduce non-motor symptoms and depression in people with Parkinson’s disease, a small study suggests. Notably, the one-month intervention, while safe, was found to have no significant effect on patients’ motor symptoms, even though they showed…
Get regular updates to your inbox.